Affomix inks antibody deal with Kalgene

Affomix has struck a deal to use its technology to generate antibodies that can be used to hit therapeutic and diagnostic targets selected by Kalgene. The deal includes financial milestones, but the two companies didn't spell them out in their release.

"Our automated high-throughput procedures allow us to quickly identify highly specific antibodies against predetermined regions of target proteins. These antibodies are well suited for experimental use while serving as ideal starting points for development of diagnostic and therapeutic agents," says Michael Sherman, the president of Affomix.

- check out the Affomix release

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.